Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Histone deacetylases (HDACs) are critical regulators of gene expression.
• HDAC inhibitors are investigated as anti-cancer therapeutics.
• Understanding inhibitor kinetics is crucial for optimizing therapeutic strategies.

Purpose of the Study:

• To identify and characterize a novel potent inhibitor targeting HDAC1 and HDAC2.
• To investigate the in vitro and in vivo properties of the identified inhibitor.
• To assess the therapeutic potential and tolerability of the inhibitor in preclinical models.

Main Methods:

• Kinetic analysis of biaryl inhibitors with isolated HDAC1 and HDAC2.
• Cell culture studies to evaluate histone hyperacetylation and gene expression changes.
• In vivo efficacy and tolerability studies in tumor-bearing mice.

Main Results:

• Biaryl inhibitors demonstrated slow binding kinetics to HDAC1 and HDAC2.
• Delayed histone acetylation and gene expression modulation were observed in vitro.
• In vivo histone acetylation persisted beyond drug clearance.
• Continuous target inhibition was well tolerated and led to tumor growth inhibition.

Conclusions:

• The potent biaryl inhibitor SHI-1:2 exhibits unique slow-binding kinetics.
• Sustained target engagement in vivo contributes to therapeutic efficacy.
• SHI-1:2 demonstrates potential as a well-tolerated anti-cancer agent with flexible dosing.